How Might Cannabis Rescheduling Change Workplace and Safety Drug Testing?

The federal landscape for cannabis is shifting rapidly as President Trump’s rescheduling order gains momentum. While moving to Schedule III is a historic win, the Department of Transportation recently clarified that federal drug testing for safety-sensitive roles won't change until the process is fully finalized. Meanwhile, bipartisan voices in Congress are already pushing for the next logical steps: banking access, sentencing reform, and total legalization. On the state level, it's a mixed bag of progress and pushback—New Jersey is advancing psilocybin therapy, while a campaign in Massachusetts just gained enough steam to try and roll back legalization via a 2026 ballot initiative.

For the everyday enthusiast, this news is a reminder that while the "Schedule III" headline is huge, the practical benefits—like job protection and easier banking—aren't instant. It’s a classic "one step forward" situation where federal policy is finally acknowledging the plant's medical value, but local and corporate rules are still catching up. Stay vigilant, because true accessibility and community freedom require these additional reforms to actually stick.